Valuation
- Market cap
- 7,423,156,000
- Revenue TTM
- $0
- Net income TTM
- $-209,130,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 27,908,900
- Avg volume
- 3,697,740
- Day's range
- $70.13 – $70.78
- Shares out
- 105,293,000
- Stochastic %K
- 43%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $55.75
Company profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or preven...
Show more
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 212 784 6595
- Website
- https://metsera.com
- Address
- 3 World Trade Center, 175 Greenwich Street, New York, United States
Latest news
No headlines yet.
